Masimo Corporation Announces Study: SedLine® Brain Function Monitoring Reduces Pediatric Anesthesia Risks and Costs

Reuters
2025/06/10
Masimo Corporation Announces Study: SedLine® Brain Function Monitoring Reduces Pediatric Anesthesia Risks and Costs

Masimo Corporation has announced the findings of a new clinical trial, published in JAMA Pediatrics, demonstrating the advantages of its SedLine® Brain Function Monitoring technology in pediatric anesthesia. The study, conducted by Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University, involved children aged 1 to 6 years undergoing elective surgery. The results showed that EEG-guided anesthesia using SedLine significantly reduced the exposure to sevoflurane, a commonly used inhalation anesthetic, and lowered the incidence of pediatric anesthesia emergence delirium (PAED). Children monitored with SedLine regained consciousness 53% sooner and were discharged from the post-anesthesia care unit 48% sooner compared to those in the control group. These outcomes suggest improvements in safety, efficiency, and cost-effectiveness of pediatric anesthesia. The findings have been presented and are available for review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Masimo Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610391732) on June 10, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10